We enroll approximately 300 patients annually on NCI NCORP and pharmaceutical industry-sponsored clinical research trials. Our Precision Cancer Therapies Program concentrates on new drug development and Phase 1.

Fellows are expected to complete a clinical research project, perform a quality/performance improvement project, and publish case reports/literature reviews during their fellowship.

Funds are available for fellows to present their research at national meetings.

Current Fellow Research

COVID-19 Related

COVID-19 in Relation to Hematological Events and Mortality in Subset of Inpatient Cancer Patients for the upcoming AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020. (Dr. Gadde)

Outcomes of patients with multiple myeloma with COVID-19 infection for the upcoming AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020. (Dr. Lunski)

Prostate cancer and COVID-19: Impact of hormonal therapy on severe outcomes for the upcoming AACR Virtual Meeting: COVID-19 and Cancer, July 20-22, 2020. (Dr. Tawagi)

Breast Cancer and COVID-19: Impact of Active Treatment on Severe Outcomes accepted for poster presentation at the 2020 San Antonio Breast Cancer Symposium®, December 8-12, 2020. (Dr. Tawagi)

Cancer patients and COVID-19 mortality. (Dr. Lunski)

Notch signaling in glioblastoma cancer stem cells. (Dr. Lunski)

Retrospective study evaluating parameters contributing to morbidity and mortality in COVID+ patients with cancer. (Dr. Tawagi)

Solid Tumors

Clinical characteristics and outcomes of patients with resectable, metastatic colorectal cancer treated with adjuvant FOLFIRI after progression on neoadjuvant FOLFOX ASCRS Accepted January 24, 2020. (Dr. Luk)

Malignant Mesothelioma and Germline Heterozygous BAP1 Mutation in a Young Woman Presenting with Recurrent Pleural Effusions and Worsening Pneumothorax After Talk Pleurodesis. Accepted CHEST 2020. (Dr. Luk)

Utilization of genomic mutational information in breast cancer patients. (Dr. Gadde)

Interest in adaptive immunotherapies, and immune-related toxicities in solid tumors. (Dr Tawagi)

Involvement in prospective clinical trial looking using regimen to augment standard immunotherapy in melanoma & genitourinary patients. (Dr. Tawagi)

Retrospective study looking at rate of autoimmune flares & irAES in patients with a pre-existing history of autoimmune disease. (Dr. Tawagi)

Abstract Accepted Dr. Tawagi: Timing of steroid doses and response rates to immune-checkpoint inhibitors in metastatic cancer. SITC 35th Anniversary Annual Meeting during SITC 2020, Virtual Poster Hall, 11/11/2020 – 11/14/2020 9a-5p. Abstract ID 247

Abstract Accepted Dr. Mukkamala: PD-1/PD-L1/CTLA-4 inhibitor therapy following progression on a different PD-1/PD-L1 inhibitor: a case series. SITC 35th Anniversary Annual Meeting during SITC 2020, Virtual Poster Hall, 11/11/2020 – 11/14/2020 9a-5p

JMCR-D-20-00712R1
Primary colon adenocarcinoma with choriocarcinoma differentiation: a case report and review of literature Jessica Boyce, MD; Karine Tawagi, MD; John T Cole, MD
Journal of Medical Case Reports - Accepted for Publication (9/29/20)

Heme/BMT

HLA type impact on myeloma transplant outcomes (Dr. Khan)

Stratify myeloma patients and process through which we take them to transplant (Dr. Khan)

Stem cell harvesting protocol in patients undergoing autologous stem cell transplant. (Dr. Lunski)

The changing molecular landscape of AML and its impact on treatment. Review Article Integr Mol Med 2020 doi: 10.15761/IMM.1000405. June 30, 2020. Dr. Lunski and Dr. Khan with Drs. Finn, Davis, Staton and Badari.

Supportive Care

Distress scores in oncology patients and subsequent interventions (Dr. Gadde)

Rate of c diff infection in neutropenic patients treated with cefepime (Dr. Luk)